FRAXIPARINE FORTE 19000 UNIT
NADROPARIN CALCIUM : 19000 UNIT · DIN 02240114 · ASPEN PHARMACARE CANADA INC.
Health Canada status: APPROVED
What is FRAXIPARINE FORTE?
FRAXIPARINE FORTE 19000 UNIT contains NADROPARIN CALCIUM : 19000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02240114, held by ASPEN PHARMACARE CANADA INC., supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 21-May-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FRAXIPARINE FORTE used for?
FRAXIPARINE® (nadroparin calcium) is indicated for the prophylaxis of thromboembolic disorders, such as those associated with general surgery and orthopedic surgery, those in high-risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure), immobilised due to acute illness or hospitalised in an intensive care unit. It is also indicated for the treatment of deep vein thrombosis, prevention of clotting during hemodialysis, and treatment of unstable angina and non-Q wave myocardial infarction. FRAXIPARINE® FORTE (nadroparin calcium) is indicated for the treatment of deep vein thrombosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is FRAXIPARINE FORTE called?
The same molecule, NADROPARIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FRAXIPARINE | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02240114 |
|---|---|
| Brand name | FRAXIPARINE FORTE |
| Generic / active ingredient | NADROPARIN CALCIUM : 19000 UNIT |
| Manufacturer | ASPEN PHARMACARE CANADA INC. |
| Strength | 19000 UNIT |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B01AB06 NADROPARIN |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 21-May-2026 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02240114 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2240114 |
| Brand name | FRAXIPARINE FORTE |
| Active ingredient / INN | NADROPARIN CALCIUM : 19000 UNIT |
| ATC code | B01AB06 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | ASPEN PHARMACARE CANADA INC. |
How is it stored and handled?
null
How is it supplied?
Cartons contain 10 prefilled glass syringes.
Which pack is which?
| Strength on the label | 19000 UNIT |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS ; INTRAVENOUS |
| Packaging as described in the monograph | Cartons contain 10 prefilled glass syringes. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code B01AB06 NADROPARIN. 0 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FRAXIPARINE | 9500 UNIT | SOLUTION | ASPEN PHARMACARE CANADA INC. | APPROVED | DIN 02236913 |
| FRAXIPARINE | 9500 UNIT | SOLUTION | ASPEN PHARMACARE CANADA INC. | APPROVED | DIN 02450615 |
| FRAXIPARINE | 9500 UNIT | SOLUTION | ASPEN PHARMACARE CANADA INC. | APPROVED | DIN 02450623 |
| FRAXIPARINE | 9500 UNIT | SOLUTION | ASPEN PHARMACARE CANADA INC. | APPROVED | DIN 02450631 |
| FRAXIPARINE | 9500 UNIT | SOLUTION | ASPEN PHARMACARE CANADA INC. | APPROVED | DIN 02450658 |
| FRAXIPARINE FORTE | 19000 UNIT | SOLUTION | ASPEN PHARMACARE CANADA INC. | APPROVED | DIN 02450666 |
| FRAXIPARINE FORTE | 19000 UNIT | SOLUTION | ASPEN PHARMACARE CANADA INC. | APPROVED | DIN 02450674 |
Who else supplies NADROPARIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NADROPARIN appears in 37 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does NADROPARIN cost around the world?
NADROPARIN is listed on 5 national price registers Nexara tracks, across 48 pack listings published on 5 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 2 | 22 | 03 Sep 2026 |
| Luxembourg | reimbursement | 8 | 8 | 05 Sep 2026 |
| Hungary | producer price (ex-factory) | 7 | 7 | 03 Sep 2026 |
| South Africa | single exit price | 6 | 6 | 01 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 5 | 5 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.